Epigenome

The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements

Retrieved on: 
Tuesday, April 9, 2024
Shenzhen University, Molecular biology, Immunology, Nature Methods, Advanced technology, Proteome, Ageing, Speech, Genesis (journal), Data analysis, Southern Medical University, Neuroscience, Translation, Human Cell Atlas, Nature Communications, Biochemistry, Neurology, Communication, Transcriptome, Genetics, Research, Genome, Epigenome, Immunity, Microbiology, Metabolome, Diagnosis, Peking University, Health, Conference, GSA, Executive, Cancer, Fudan University, Reproduction, Biology, National academy, Zhejiang University, Medicine

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.

Key Points: 
  • SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.
  • With the theme "Technologic Innovation, Scientific Discovery, Translational Application", TICSSO-2 focused on the latest advances in single-cell and spatial omics.
  • On March 31st and April 1st were four online international forums, with one specifically for young researchers.
  • TICSSO-2 is hailed as the largest, most influential, and highest academic conference in the field of single-cell and spatial omics in the world.

Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes

Retrieved on: 
Wednesday, March 27, 2024
Cardiology, Civil service commission, Health, Cardiovascular disease, Pseudogene, Cell, Genetics, Mental, Abraxis BioScience, Patient, Female, Cancer, University, Biology, Biobank, Epigenome, Genomics, European Commission, Economics, Medicine, Pharmaceutical industry

MENLO PARK, Calif., March 27, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that the University of Tartu, host of Estonia's National Biobank, has chosen the Revio HiFi sequencing system to sequence 10,000 whole human genomes and unlock new insights from its populational health data. The announcement follows funding from the European Commission and the Estonian government to help Estonia adopt personalized medicine at scale and adapt public health systems to the biology of its population. The University will also support the European Union's 1+ Million Genomes initiative, which seeks to boost innovation in healthcare across Europe.

Key Points: 
  • The University will also support the European Union's 1+ Million Genomes initiative , which seeks to boost innovation in healthcare across Europe.
  • 10,000 whole human genomes will be sequenced and analyzed by the Institute of Genomics at the University of Tartu using Revio.
  • "The team chose PacBio HiFi technology over other long- and short-read offerings because of its ability to sequence complete and accurate genomes at competitive economics and scale.
  • In addition to this 10,000-genome project, the Biobank team is looking to secure funding to sequence the entire biobank of over 200,000 samples to drive advances in health care globally.

Ludwig Enterprises Inc. (OTC:LUDG) Announces Patent Filing for Breakthrough in Identifying mRNA Genes Associated with Certain Cancers

Retrieved on: 
Wednesday, March 6, 2024
Breast cancer, Neoplasm, Messenger, Epigenome, OTC, Cancer, Bladder cancer, Stem cell, IRB, Breast, Biomarker, Element, Cytokine, Patent, Patient, Gene, Medicine, Thermo Fisher Scientific, Disease, Diagnosis, Machine learning, Trial of the century, Colorectal cancer, DNA, Environment, Vaccine

The Company’s mRNA for Life™ is a one-of-the-kind noninvasive at-home sceening test for genes that could be associated with cancer.

Key Points: 
  • The Company’s mRNA for Life™ is a one-of-the-kind noninvasive at-home sceening test for genes that could be associated with cancer.
  • This test allows a person to make themselves a priority and could be a signal to seek a medical examination.
  • The Company selected for measurement 48 distinct mRNA genes in stored specimens from patients afflicted with breast, bladder or colorectal cancer.
  • mRNA levels were analyzed using machine learning artificial intelligence (AI) to identify markers of genetic expression involved in separate cancers.

Comprehensive Study from 50 Top Scientists Details Five Cutting-edge Advances in Biomedical Engineering and Their Applications in Medicine

Retrieved on: 
Thursday, February 22, 2024
Health Technology, Data Management, Technology, Nanotechnology, Stem Cells, Biometrics, Medical Devices, Neurology, Genetics, Artificial Intelligence, Science, Biotechnology, Other Science, Health, Research, Paper, Therapy, Tissue engineering, Transcriptome, Gene editing, AI, Education, Substance abuse, Immunotherapy, Epigenome, Growth, Physiology, Interface, Cell, Vaccine, Behavior, Protein engineering, Biomedicine, University, Biomedical engineering, Guideline, Biological engineering, Patient, Genome, Johns Hopkins University, Genomics, Diagnosis, Tissue, DNA, Immune system, Brain, Medical imaging

Through the course of the workshop, the researchers identified five primary medical challenges that have yet to be addressed, but, by solving them with advanced biomedical engineering approaches, can greatly improve human health.

Key Points: 
  • Through the course of the workshop, the researchers identified five primary medical challenges that have yet to be addressed, but, by solving them with advanced biomedical engineering approaches, can greatly improve human health.
  • By focusing on these five areas, the consortium has laid out a roadmap for future research and funding.
  • Advanced technologies, such as wearable sensors and digital twins, can provide the basis of a solution to this challenge.
  • Despite the rapid advances in genomics in the past few decades, there are obstacles remaining in our ability to engineer genomic DNA.

Kimera® Labs Inc publishes novel brain targeting of exosomes in Nature Scientific Reports

Retrieved on: 
Tuesday, February 20, 2024
BBB, Publishing, Multimedia, Epigenome, Exosome, Non-profit hospital, City, Regenesis, Neurology, Scientific Reports, Patient, Labs, MSC, UCLA, Brain, Medical imaging

The article, "Use of transcranial low-intensity focused ultrasound for targeted delivery of stem cell-derived exosomes to the brain" was published on October 18, 2023 in Nature Scientific Reports.

Key Points: 
  • The article, "Use of transcranial low-intensity focused ultrasound for targeted delivery of stem cell-derived exosomes to the brain" was published on October 18, 2023 in Nature Scientific Reports.
  • The study findings published in Nature Scientific Reports concluded that a statistically significant amount of Kimera®'s exosomes penetrated the BBB by employing focused ultrasound on a targeted region of the rat brain.
  • Kimera®'s neural study employing exosomes combined with focused ultrasound is considered a material advancement by the scientific community in the challenging targeted brain delivery field.
  • The Company is in the process of advancing further neural scientific and clinical developments with its exosomes employing focused ultrasound.

Kimera® Labs Inc publishes novel brain targeting of exosomes in Nature Scientific Reports

Retrieved on: 
Tuesday, February 20, 2024
BBB, Publishing, Epigenome, Exosome, Non-profit hospital, City, Regenesis, Neurology, Scientific Reports, Patient, Labs, MSC, UCLA, Brain, Medical imaging

The article, "Use of transcranial low-intensity focused ultrasound for targeted delivery of stem cell-derived exosomes to the brain" was published on October 18, 2023 in Nature Scientific Reports.

Key Points: 
  • The article, "Use of transcranial low-intensity focused ultrasound for targeted delivery of stem cell-derived exosomes to the brain" was published on October 18, 2023 in Nature Scientific Reports.
  • The study findings published in Nature Scientific Reports concluded that a statistically significant amount of Kimera®'s exosomes penetrated the BBB by employing focused ultrasound on a targeted region of the rat brain.
  • Kimera®'s neural study employing exosomes combined with focused ultrasound is considered a material advancement by the scientific community in the challenging targeted brain delivery field.
  • The Company is in the process of advancing further neural scientific and clinical developments with its exosomes employing focused ultrasound.

ReAlta Life Sciences Strengthens Board of Directors with Appointment of Two Accomplished Biotechnology Innovators

Retrieved on: 
Wednesday, January 24, 2024
Research, Clinical Trials, Health Technology, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Artificial intelligence, NSRI, University, Patient, Principal, Executive Committee, UARC, Government, JHUAPL, Partnership, Containerization, Epigenome, GSK, Diagnosis, DTRA, Drug discovery, Chemical engineering, COVID-19, Applied Physics Laboratory, Biomedical engineering, CBCS, Department of Defence, DARPA, Therapy, Doctor of Philosophy, Traumatic brain injury, Nursing care plan, Machine learning, Pennsylvania State University, STRATCOM, MRIGlobal, SVP, ARA, Medical device

“We are delighted to welcome Dr. Baldoni and Dr. Van Gieson to our Board of Directors and look forward to their expertise as we continue to advance our EPICC platform beyond our current portfolio,” said Buzz Heidt, Chairman of ReAlta’s Board of Directors.

Key Points: 
  • “We are delighted to welcome Dr. Baldoni and Dr. Van Gieson to our Board of Directors and look forward to their expertise as we continue to advance our EPICC platform beyond our current portfolio,” said Buzz Heidt, Chairman of ReAlta’s Board of Directors.
  • Dr. Baldoni’s Platform Technology and Science team supported the development of small molecules, biopharmaceuticals and cell and gene therapy modalities from discovery through commercialization.
  • Dr. Baldoni stepped away from that leadership role in 2017 to start the first AI-driven drug discovery unit at GSK.
  • After retiring from GSK in 2019, he spent a year as the Chief Technology Officer of a stealth AI-enabled drug discovery startup.

Illumina Presents: The Illumina Epigenetics Experience Virtual Event

Retrieved on: 
Tuesday, January 23, 2024
SAN, DNA, EPIC, Epigenome, Research, Health, NYU Langone Health

SAN DIEGO, Jan. 23, 2024 /PRNewswire-PRWeb/ -- Illumina, a pioneer in innovative technologies for genetic analysis, is excited to announce "The Illumina Epigenetics Experience," a virtual event scheduled for Wednesday, January 31st, 2024. The event is set to begin at 10:00 AM Eastern Standard Time and will offer a 3-hour exploration into the rapidly advancing field of epigenetics.

Key Points: 
  • Illumina's virtual event "The Illumina Epigenetics Experience," scheduled for January 31, 2024, will showcase the latest advancements in epigenetics with expert presentations and provide networking opportunities for industry professionals
    SAN DIEGO, Jan. 23, 2024 /PRNewswire-PRWeb/ -- Illumina, a pioneer in innovative technologies for genetic analysis, is excited to announce " The Illumina Epigenetics Experience ," a virtual event scheduled for Wednesday, January 31st, 2024.
  • This unique virtual gathering is designed for industry scientists, government personnel, and academic researchers keen on the latest developments in epigenetics.
  • Interactive Virtual Exhibit Hall: Explore a virtual exhibit hall featuring a wealth of educational content, detailed information about Illumina technology products, and case studies showcasing significant research.
  • To register for "The Illumina Epigenetics Experience" or to find out more, click here .

Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform

Retrieved on: 
Sunday, January 7, 2024
Cloud, Epigenome, Partnership, Transcriptome, Akoya, Mary Ann Liebert, Laboratory, Genomics, AI, University, Proteomics, Proteome, Metabolome, Nature, Genetic, GEN, Acceleration, Medical imaging

MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, in collaboration with Enable Medicine, a leading provider of AI-powered biological insights, announces the availability of MaxFuse, an advanced algorithm co-developed in the laboratory of Dr. Garry Nolan for integrating multiomic single-cell and spatial datasets*. Dr. Nolan is a co-founder and member of the Board of Directors of Akoya Biosciences.

Key Points: 
  • Dr. Nolan is a co-founder and member of the Board of Directors of Akoya Biosciences.
  • Recent technology advancements have enabled analyses of the proteome, metabolome, transcriptome, and epigenome both spatially and at the single-cell level.
  • “MaxFuse represents a significant advancement in the analytics capabilities needed to maximize the value of data derived from spatial and single-cell technologies.
  • * MaxFuse was developed in collaboration with the laboratories of Nancy Zhang and Zongming Ma at the University of Pennsylvania.

Moonwalk Biosciences Launches with $57 Million in Financing to Advance a New Class of Precision Epigenetic Medicines

Retrieved on: 
Thursday, January 4, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Biology, Epigenome, Entrepreneurship, Broad Institute, Howard Hughes Medical Institute, Gene editing, Moonwalk, Multimedia, Software, MIT, DRS, Disease, DNA, CBO, AI, ARCH Venture Partners, ARCH, Engineering, Gene, Harvard University, Khosla Ventures, Genome, GV

The financing will support continued advancement of Moonwalk’s epigenetic profiling and engineering technology platform and progress its pipeline of epigenetic therapeutics towards the clinic.

Key Points: 
  • The financing will support continued advancement of Moonwalk’s epigenetic profiling and engineering technology platform and progress its pipeline of epigenetic therapeutics towards the clinic.
  • View the full release here: https://www.businesswire.com/news/home/20240104793936/en/
    Moonwalk Biosciences founding team (from left to right): Alex Aravanis, CEO, Justin Valley, COO, Elaine Cheung, CBO, Arash Jamshidi, President & CTO.
  • Moonwalk is the first company that couples an epigenetic discovery platform with precise engineering – opening up the epigenome as a new target space for complex diseases.
  • We look forward to what new innovations Moonwalk can advance in epigenetic engineering,” said Robert Nelsen, Managing Director and Co-Founder, ARCH Venture Partners.